Sven Francque

34.0k total citations · 12 hit papers
194 papers, 9.1k citations indexed

About

Sven Francque is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Sven Francque has authored 194 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 157 papers in Epidemiology, 84 papers in Hepatology and 57 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Sven Francque's work include Liver Disease Diagnosis and Treatment (148 papers), Diet, Metabolism, and Disease (50 papers) and Liver Disease and Transplantation (41 papers). Sven Francque is often cited by papers focused on Liver Disease Diagnosis and Treatment (148 papers), Diet, Metabolism, and Disease (50 papers) and Liver Disease and Transplantation (41 papers). Sven Francque collaborates with scholars based in Belgium, France and United Kingdom. Sven Francque's co-authors include Luisa Vonghia, Luc Van Gaal, Wilhelmus J. Kwanten, Bart Staels, P. Michielsen, An Verrijken, Denise van der Graaff, Joel T. Haas, Vlad Ratziu and Elisabetta Bugianesi and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Sven Francque

178 papers receiving 8.9k citations

Hit Papers

EASL–EASD–EA... 2014 2026 2018 2022 2024 2016 2014 2016 2020 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
    2024 585 citations Vlad Ratziu, Elisabetta Bugianesi et al. Journal of Hepatology profile →
  2. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
    2016 581 citations Sven Francque, Luc Van Gaal et al. profile →
  3. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
    2014 454 citations Sven Francque, Luc Van Gaal et al. profile →
  4. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications
    2016 394 citations Sven Francque, Denise van der Graaff et al. Journal of Hepatology profile →
  5. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
    2020 280 citations Vlad Ratziu, Arun J. Sanyal et al. Hepatology profile →
  6. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
    2023 267 citations Philip N. Newsome, Sven Francque et al. Hepatology profile →
  7. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
    2020 228 citations Sven Francque, Manal F. Abdelmalek et al. profile →
  8. Non-alcoholic fatty liver disease: A patient guideline
    2021 162 citations Sven Francque, Juan Manuel Mendive et al. JHEP Reports profile →
  9. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight
    2022 156 citations Sven Francque, Elisabetta Bugianesi et al. profile →
  10. Steatotic liver disease
    2024 95 citations Sven Francque et al. profile →
  11. Therapeutic management of metabolic dysfunction associated steatotic liver disease
    2024 54 citations Jing Zeng, Jian‐Gao Fan et al. United European Gastroenterology Journal profile →
  12. EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary
    2024 47 citations Vlad Ratziu, Elisabetta Bugianesi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sven Francque Belgium 48 7.3k 3.2k 2.9k 1.5k 1.5k 194 9.1k
Naim Alkhouri United States 59 8.7k 1.2× 3.8k 1.2× 3.9k 1.3× 1.7k 1.2× 1.9k 1.3× 325 11.2k
Mohammed Eslam Australia 37 8.4k 1.1× 3.9k 1.2× 3.3k 1.1× 1.5k 1.0× 1.1k 0.7× 123 9.6k
Jörn M. Schattenberg Germany 50 6.7k 0.9× 3.4k 1.1× 2.5k 0.9× 1.6k 1.1× 1.5k 1.0× 332 9.2k
Paola Dongiovanni Italy 57 6.5k 0.9× 2.2k 0.7× 2.8k 1.0× 1.5k 1.0× 1.1k 0.7× 188 9.1k
Anna Ludovica Fracanzani Italy 59 6.2k 0.9× 2.6k 0.8× 2.5k 0.9× 1.2k 0.8× 1.1k 0.7× 217 9.4k
Mazen Noureddin United States 49 7.1k 1.0× 3.9k 1.2× 2.7k 0.9× 1.3k 0.9× 1.3k 0.9× 272 9.1k
Silvia Fargion Italy 62 7.3k 1.0× 3.1k 1.0× 2.9k 1.0× 1.6k 1.0× 1.1k 0.8× 267 11.6k
Yao‐Chang Liu United States 6 7.8k 1.1× 3.4k 1.1× 2.8k 1.0× 1.5k 1.0× 1.5k 1.0× 9 9.1k
Timothy Hardy United Kingdom 16 5.8k 0.8× 2.5k 0.8× 2.4k 0.8× 1.7k 1.1× 886 0.6× 23 7.5k
Gianluca Svegliati‐Baroni Italy 47 6.1k 0.8× 3.2k 1.0× 2.3k 0.8× 2.4k 1.6× 1.7k 1.2× 132 9.2k

Countries citing papers authored by Sven Francque

Since Specialization
Citations

This map shows the geographic impact of Sven Francque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Francque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Francque more than expected).

Fields of papers citing papers by Sven Francque

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Francque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Francque. The network helps show where Sven Francque may publish in the future.

Co-authorship network of co-authors of Sven Francque

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Francque. A scholar is included among the top collaborators of Sven Francque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Francque. Sven Francque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Steenkiste, Christophe Van, et al.. (2025). Prevalence and Risk Factors of MASLD in Prediabetes and Type 2 Diabetes Mellitus in Belgium and The Netherlands. Biomedicines. 13(11). 2821–2821.
2.
Mouillot, Thomas, Luisa Vonghia, Charlotte Costentin, et al.. (2025). Non-invasive tests for fibrotic MASH for reducing screen failure in therapeutic trials. JHEP Reports. 7(4). 101351–101351. 4 indexed citations
3.
Zeng, Jing, Jian‐Gao Fan, & Sven Francque. (2024). Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterology Journal. 12(2). 177–186. 54 indexed citations breakdown →
4.
Lionis, Christos, Sophia Papadakis, Marilena Anastasaki, et al.. (2024). Practice Recommendations for the Management of MASLD in Primary Care: Consensus Results. SHILAP Revista de lepidopterología. 12(8). 180–180. 5 indexed citations
5.
Witte, Chloë De, Heiko U. De Schepper, Wouter Van Moerkercke, et al.. (2023). Clinical significance and impact of gastric non‐Helicobacter pylori Helicobacter species in gastric disease. Alimentary Pharmacology & Therapeutics. 57(12). 1432–1444. 12 indexed citations
6.
Eyck, Annelies Van, Wilhelmus J. Kwanten, Cédric Peleman, et al.. (2023). The role of adipose tissue and subsequent liver tissue hypoxia in obesity and early stage metabolic dysfunction associated steatotic liver disease. International Journal of Obesity. 48(4). 512–522. 6 indexed citations
7.
Ratziu, Vlad, Stephen A. Harrison, V. Loustaud‐Ratti, et al.. (2022). Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH. Journal of Hepatology. 78(3). 479–492. 73 indexed citations
8.
Graaff, Denise van der, Benedicte Y. De Winter, Joris De Man, et al.. (2021). Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD. JHEP Reports. 4(2). 100412–100412. 27 indexed citations
9.
Francque, Sven, Pierre Bédossa, Vlad Ratziu, et al.. (2020). The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the NATIVE Phase 2b trial. Hepatology. 72. 18 indexed citations
10.
Janssens, Annelies, Luisa Vonghia, P. Michielsen, et al.. (2020). Nivolumab and anti-HCV activity, a case report. Acta Clinica Belgica. 76(5). 392–396. 3 indexed citations
11.
Newsome, Philip N., Sven Francque, Stephen A. Harrison, et al.. (2019). Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Alimentary Pharmacology & Therapeutics. 50(2). 193–203. 144 indexed citations
12.
Somers, Michaël, et al.. (2018). Manometric and ultrasonographic characteristics of patients with coexisting fecal incontinence and constipation.. PubMed. 80(4). 463–469. 2 indexed citations
13.
Wargny, Matthieu, Pierre‐Henri Ducluzeau, Jean‐Michel Petit, et al.. (2018). Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. Atherosclerosis. 278. 82–90. 32 indexed citations
14.
Ceuleers, Hannah, Nikita Hanning, Jurgen Joossens, et al.. (2018). Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post‐inflammatory rat model for irritable bowel syndrome. British Journal of Pharmacology. 175(17). 3516–3533. 36 indexed citations
15.
Dongen, Stefan Van, et al.. (2018). Parameters influencing the quality of colonoscopy in Belgium : a critical evaluation.. PubMed. 81(1). 29–38. 5 indexed citations
16.
Zhou, You, Matej Orešič, Marja Leivonen, et al.. (2016). Noninvasive Detection of Nonalcoholic Steatohepatitis Using Clinical Markers and Circulating Levels of Lipids and Metabolites. Clinical Gastroenterology and Hepatology. 14(10). 1463–1472.e6. 114 indexed citations
17.
Michielsen, P., et al.. (2012). Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?. PubMed. 58(1). 65–79. 8 indexed citations
18.
Francque, Sven, et al.. (2012). Vitamin C as well as β-carotene attenuates experimental liver fibrosis after intoxication with carbon tetrachloride in rats. International Journal of Biological and Chemical Sciences. 6(2). 6 indexed citations
19.
Francque, Sven, Stéphane De Maeght, Maciej Adler, et al.. (2011). High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry.. PubMed. 74(1). 9–16. 16 indexed citations
20.
Verrijken, An, Sven Francque, & Luc Van Gaal. (2010). The Role of Visceral Adipose Tissue in the Pathogenesis of Non-alcoholic Fatty Liver Disease. touchREVIEWS in Endocrinology. 7(2). 96–96. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naim Alkhouri Breakdown of academic impact, for papers by Mohammed Eslam Breakdown of academic impact, for papers by Jörn M. Schattenberg Breakdown of academic impact, for papers by Paola Dongiovanni Breakdown of academic impact, for papers by Anna Ludovica Fracanzani Breakdown of academic impact, for papers by Mazen Noureddin Breakdown of academic impact, for papers by Silvia Fargion Breakdown of academic impact, for papers by Yao‐Chang Liu Breakdown of academic impact, for papers by Timothy Hardy Breakdown of academic impact, for papers by Gianluca Svegliati‐Baroni
Rankless by CCL
2026